Cibus, Inc. (CBUS)
NASDAQ: CBUS · Real-Time Price · USD
1.610
-0.040 (-2.42%)
At close: Jul 25, 2025, 4:00 PM
1.610
0.00 (-0.01%)
After-hours: Jul 25, 2025, 4:00 PM EDT
Cibus Revenue
Cibus had revenue of $1.03M in the quarter ending March 31, 2025, with 89.72% growth. This brings the company's revenue in the last twelve months to $4.75M, up 104.78% year-over-year. In the year 2024, Cibus had annual revenue of $4.26M with 134.56% growth.
Revenue (ttm)
$4.75M
Revenue Growth
+104.78%
P/S Ratio
9.30
Revenue / Employee
$29,881
Employees
159
Market Cap
80.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.26M | 2.45M | 134.56% |
| Dec 31, 2023 | 1.82M | 1.66M | 1,057.32% |
| Dec 31, 2022 | 157.00K | -25.83M | -99.40% |
| Dec 31, 2021 | 25.99M | 2.14M | 8.96% |
| Dec 31, 2020 | 23.85M | 16.56M | 226.91% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| Novartis AG | 55.19B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
CBUS News
- 4 weeks ago - The U.S. Food and Drug Administration Completes Review of Cibus' Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed - GlobeNewsWire
- 6 weeks ago - Cibus and John Innes Centre Announce Ongoing Collaboration with Potential to Revolutionize Fertilizer Use in Farming - GlobeNewsWire
- 6 weeks ago - Cibus, Inc. Announces Closing of $27.5 Million Public Offering - GlobeNewsWire
- 7 weeks ago - USDA Designates Cibus' Herbicide Tolerance Canola Trait HT2 as Not Regulated Under USDA's Biotechnology Regulations - GlobeNewsWire
- 7 weeks ago - Cibus, Inc. Announces Pricing of $27.5 Million Public Offering - GlobeNewsWire
- 7 weeks ago - Cibus, Inc. Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - Cibus Provides Webcast of BofA Securities AgTech Virtual Conference Fireside Chat - GlobeNewsWire
- 2 months ago - Cibus to Participate in Alliance Global Partner's Annual Virtual Healthcare Company Showcase - GlobeNewsWire